Comparing SG&A Expenses: Amgen Inc. vs GSK plc Trends and Insights

A Decade of SG&A Expenses: Amgen Inc. vs GSK plc

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, from 2014 to 2023, Amgen Inc. and GSK plc have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Amgen's SG&A expenses have grown by approximately 31%, peaking in 2023, while GSK's expenses have fluctuated, with a notable dip in 2022. This divergence highlights Amgen's consistent investment in operational efficiency, whereas GSK's strategy appears more variable. Notably, GSK's expenses were consistently higher, averaging around 85% more than Amgen's. These insights reflect broader strategic priorities, with Amgen focusing on steady growth and GSK adapting to market dynamics. As the pharmaceutical landscape continues to shift, these financial trends offer a window into the competitive strategies of these industry giants.